^
CANCER:

Ocular Melanoma





Show legend
Group by Gene:
Include preclinical:

dacarbazine
temozolomide
0
DNA synthesis inhibitor
melphalan hepatic delivery system
mitomycin
cisplatin
bleomycin
PD1 inhibitor
1
PD1 inhibitor
pembrolizumab
nivolumab
2
MEK inhibitor
trametinib
selumetinib
3
CTLA4 inhibitor
CTLA4 inhibitor
ipilimumab
4
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
pembrolizumab + ipilimumab
5
Bcl2 inhibitor, Tubulin inhibitor
albumin-bound paclitaxel
6
gp100 inhibitor, CTLA4 inhibitor
ipilimumab + tebentafusp-tebn
7
gp100 inhibitor
tebentafusp-tebn
8
MEK inhibitor, BRAF inhibitor
trametinib + dabrafenib
AEB071
9
PKC inhibitor
IDE196
AEB071 + AHT956
10
Multi-tyrosine kinase inhibitor
cabozantinib capsule
ponatinib
11
BRAF inhibitor, BRAF V600E inhibitor
vemurafenib
12
Immunotherapy
Immunotherapy
13
Chemotherapy
CaT
TC
14
PD-L1 inhibitor
PD-L1 inhibitor
15
FGFR inhibitor, EZH2 inhibitor
FGFR inhibitor + EZH2 inhibitor
16
Tubulin polymerization promoter, Bcl2 inhibitor
paclitaxel
17
HDAC inhibitor, HDAC1 inhibitor, PD1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
pembrolizumab + entinostat
18
cRAF inhibitor, PD1 inhibitor, MEK inhibitor, BRAF inhibitor
pembrolizumab + binimetinib + encorafenib
19
GPNMB-targeted antibody-drug conjugate, Microtubule inhibitor
CDX-011
20
THF dehydrogenase inhibitor, Arginine depleter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
cisplatin + pemetrexed + pegargiminase
21
MEK inhibitor, Reactive oxygen species stimulant, Apoptosis stimulant, HSP70 stimulant
binimetinib + STA-4783
22
MEK2 inhibitor, MEK1 inhibitor
REC-4881
U0126
23
PI3K inhibitor, PKCβ inhibitor, AKT inhibitor
enzastaurin
24
Topoisomerase II inhibitor
zoptarelin doxorubicin
25
CDK inhibitor
SNS-032
26
HDAC inhibitor
JNJ 26481585
27
MEK inhibitor, PI3K inhibitor, mTOR inhibitor
trametinib + GSK2126458
28
MEK inhibitor, mTOR inhibitor
selumetinib + AZD8055
29
GNAQ inhibitor, NMT-1 inhibitor, NLRP3 inhibitor, ARF6 inhibitor
Tris DBA
30
Gαq-11 protein inhibitor
FR900359
31
MEK inhibitor, PKC inhibitor
binimetinib + AEB071
PD-0325901 + AEB071
32
MDM2 inhibitor, PKC inhibitor
AEB071 + CGM097
33
Reactive oxygen species stimulant, Photosensitizer
verteporfin
34
mTOR inhibitor, PKC inhibitor
everolimus + AEB071
35
BET inhibitor
JQ-1
36
Phospholipase A2 inhibitor, MEK inhibitor, Immunomodulator
trametinib + hydroxychloroquine
37
Reactive oxygen species stimulant, Apoptosis stimulant, HSP70 stimulant
STA-4783
38
Aurora kinase B inhibitor, Aurora kinase C inhibitor
NMI-900
39
DNA synthesis inhibitor, DNA-directed DNAP inhibitor
cytarabine
40
Topoisomerase I inhibitor
camptothecin nanosomal
41
EphB4 inhibitor
BHG712
42
CXCL12 inhibitor, Farnesyl transferase inhibitor
tipifarnib
43
MEK inhibitor, Gαq-11 protein inhibitor, Purinergic receptor P2Y12 inhibitor
MEK inhibitor + YM-254890
No biomarker
HLA-A*02:01
BRAF V600E
BRAF V600
BRAF mutation
GNAQ mutation
GNAQ Q209L
GNAQ Q209P
GNAQ R183Q
GNAQ G48V
LDH-L
GNA11 Q209L
MBD4 mutation
GNA11 mutation
MBD4 L563T
MBD4 deletion
LDH elevation
GOLM1 overexpression
ASS1 negative
IL6 elevation
PCSK9 underexpression
CXCL10 elevation
GPNMB expression
GNAQ G48L + FGFR4 C172G
MLANA expression + SOX10 expression
GNAQ mutation + GNA11 mutation
CYSLTR2 L129Q
KDELR3 overexpression
BAP1 deletion
NRAS overexpression
BAP1 mutation
GNRH1 expression
CDK7 overexpression
CDK9 overexpression
DDX43 overexpression
KRAS overexpression